T5	Medication 37 39	IS
T6	Medication 44 47	MMF
T8	HealthState 107 114	stabile
T9	Process 115 127	NTX Funktion
T10	LabValues 135 138	DSA
T11	Condition 146 157	Rejektionen
A2	Factuality T11 negative
R3	has_State arg1:T9 arg2:T8	
T3	Medication 61 64	Tac
T4	Measure 52 60	low dose
R1	has_Measure arg1:T3 arg2:T4	
T2	LabValues 13 15	PU
A1	Risk T2 increase_symptom
T7	Condition 16 30	DD IgA Rezidiv
A3	Factuality T7 speculated
A4	Risk T7 decrease_symptom
T12	Temporal 0 15	progrediente PU
A5	Temporal_Element T12 past_present
T13	Measure 31 36	duale
R4	has_Measure arg1:T5 arg2:T13	
T14	Temporal 31 89	duale IS mit MMF und low dose Tac bei Einschluss in Studie
A6	Temporal_Element T14 past_present
A7	Risk T5 increase_risk_factor
A8	Risk T9 decrease_symptom
A9	Factuality T10 negative
A10	Risk T10 decrease_risk_factor
A11	Risk T11 decrease_risk_factor
T16	Temporal 107 139	stabile NTX Funktion, keine DSA,
A12	Temporal_Element T16 present
T17	Temporal 140 164	keine Rejektionen bisher
A13	Temporal_Element T17 past
T15	Conclusion 90 104	dagegen sprich
